Why the study?
To elucidate criteria used to evaluate CRT response rates and highlight the concept of the CRT super-responder.
Does cardiac resynchronization therapy improve clinical outcomes in patients with refractory cardiac insufficiency?
Does cardiac resynchronization therapy improve clinical outcomes in patients with refractory cardiac insufficiency?
This review elucidates the criteria for evaluating CRT response rates and highlights the concept of the CRT super-responder, noting that up to 70% of patients respond to therapy.
Cardiac resynchronization therapy (CRT) emerged as a therapeutic modality for patients with cardiac insufficiency (CI) refractory to pharmacological treatment. Over the last 20 years, several clinical studies have sought to establish their benefits in different populations. The review of the results of these studies has shown that in patients with advanced CI (functional class (FC) I, II, III and IV of the New York Heart Association (NYHA) CRT produces consistent improvements in quality of life, FC and exercise capacity, as well as reducing hospitalizations and mortality rates. Up to 70% of patients submitted to CRT evolve as responders. The criteria adopted in the evaluation of the CRT response rate will be elucidated in this article, in which the main objective is to highlight the concept of the CRT super-responder.
No takes yet. Share an insight, caveat, or question.
de et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: